Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Rifampicin-resistant/multidrug-resistant (RR/MDR) and extensively drug-resistant (XDR) strains of M. tuberculosis (TB) are serious public health problem in Kazakhstan. In 2012 and 2013, stringent regulatory authorities approved the first new TB drugs in fifty years, bedaquiline and delamanid, offeri...

Full description

Bibliographic Details
Main Authors: Shynar M. Maretbayeva, Anar S. Rakisheva, Malik M. Adenov, Lyazzat T. Yeraliyeva, Yerkebulan Zh. Algozhin, Assel T. Stambekova, Elmira A. Berikova, Askar Yedilbayev, Michael L. Rich, Kwonjune J. Seung, Assiya M. Issayeva
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:International Journal of Infectious Diseases
Subjects:
tuberculosis
multidrug-resistant
extensively drug-resistant tuberculosis
antitubercular agents
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221002939

Internet

http://www.sciencedirect.com/science/article/pii/S1201971221002939

Similar Items